MASLD/MASH Learning Center
Advancing Care in Metabolic-Associated Steatohepatitis
Your Comprehensive Hub for Excellence in Education on MASLD/MASH
Through expert interviews, case discussions, expert panels, and patient perspectives, leading global experts deliver the latest evidence-based guidance and real-world outcomes for practicing clinicians. Join our growing community of endocrinology, obesity medicine, primary care, gastroenterology and hepatology providers by engaging with the educational content in this learning center and sharing it with your colleagues in your healthcare team.
Together, we can advance the standard of MASLD/MASH care worldwide!
It is estimated that by 2030 and 2050, 101.2 million and 121.9 million adults in the US will have MASLD.1
It is estimated that in 2020, 14.9 million adults in the US had MASH, which is expected to increase to 23.2 million by 2050.1
MASLD is the most common cause of chronic liver disease and is projected to become the leading indication for liver transplant in the US.1
Cardiovascular disease is the leading cause of morbidity and mortality in patients with MASLD.2
Educational Activities
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair's Perspective
Chairperson's Perspective: Treating At-Risk MASH: What Are You Waiting For?
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair's Perspective
Resource Center
Discover a curated collection of foundational, practical, cutting-edge and real-world educational resources at your fingertips.
Faculty
Meet our distinguished team of experts dedicated to advancing MASLD/MASH care and education worldwide.
Naim Alkhouri, MD, FAASLD, DABOM
Mazen Noureddin, MD, MHSc
Meena B. Bansal, MD, FAASLD
Fernando Bril, MD
Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP
Jennifer R. Berg
Mary E. Rinella, MD, FAASLD
